 The FDA issued a Complete Response Letter CRL related to Omeros Corporations NASDAQ: OMER marketing application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA. Related: Why Are Omeros Shares Plunging On Friday? 